Intrinsic coagulation tenase complex (Intrinsic tenase)

The intrinsic coagulation tenase complex is a multi-component enzyme assembly essential for the propagation phase of the blood coagulation cascade. It consists of the serine protease activated Factor IX (FIXa), the protein cofactor activated Factor VIII (FVIIIa), calcium ions, and a procoagulant phospholipid surface, typically provided by activated platelets (StatPearls, 2023). The primary function of this complex is to catalyze the conversion of Factor X to Factor Xa, a process that is several orders of magnitude more efficient when the complex is assembled compared to FIXa alone (PubMed, PMID: 11012661). Deficiencies in the components of this complex result in the X-linked bleeding disorders Hemophilia A (Factor VIII deficiency) and Hemophilia B (Factor IX deficiency) (NIH, 2022). Therapeutic interventions often focus on restoring the activity of this complex, either through replacement of the missing factors or via bispecific antibodies like emicizumab, which mimics the cofactor function of Factor VIIIa by bridging Factor IXa and Factor X (UniProt, P00451). Because of its central role in thrombin generation, the intrinsic tenase complex is also a potential target for anticoagulant therapies aimed at preventing thrombosis with a lower risk of bleeding compared to traditional anticoagulants.

Other names

Intrinsic tenaseFIXa-FVIIIa complexFactor IXa-Factor VIIIa complexTenase complex

Replacement of deficient factors (Factor VIII or Factor IX) to restore complex assembly; bispecific antibodies (e.g., emicizumab) mimic the cofactor function of Factor VIIIa by bridging Factor IXa and Factor X to facilitate Factor X activation.